Development and analysis of a collagen-based hemostatic adhesive.
BACKGROUND
Commercially available hemostatic-adhesive has the risk of disease transmission because it is derived from a plasma component. The purpose of this study is to manufacture a new hemostatic adhesive and evaluate its performances.


METHODS
Two atelocollagen-based hemostatic adhesives were produced and named as Bleestop A (2% esterified atelocollagen in 75% ethanol + 1% CaCl(2) + 0.71% DOPA + 0.1% tranexamic acid in DW) and Bleestop B (2% esterified atelocollagen in DW + 1% CaCl(2) + 0.71% DOPA + 0.1% aminocaproic acid in DW). These are compared with the negative control group (no adhesives used group) and the positive control group (Tissucol Duo Quick group). The adult male Sprague-Dawley rat model was adopted and the hemostatic-adhesion activities of each group were assessed by the adhesion strength test and the morphologic features of adhesion. The liver tissues were used. Histologic assessment of adhesion was accessed using light microscopy.


RESULTS
Bleeding was controlled immediately after application of Bleestop A and partial adhesion was observed after 30 s. More than 95% area of the resected surface attached after 1 min. In Bleestop B, partial adhesion was observed after 30 s. More than 95% area of the resected surface was attached after 45 s. Histologic evaluation showed that Bleestop A and B mediated organized adhesion rapidly between both resected tissue surfaces. The adhesion strength of Bleestop A and B was better than the negative control group and showed same adhesion strength as the positive control group after 3 min.


CONCLUSIONS
Bleestop A and B showed significant hemostasis and adhesion capability within 1 min. They are comparable to the positive control group.
Baik
Seung Hyuk
SH
Department of Medical Engineering, Yonsei University College of Medicine, Seoul, Korea.
Kim
Jae Hyung
JH
Cho
Hyun Hee
HH
Park
Si-Nae
SN
Kim
Yu Seun
YS
Suh
Hwal
H
D000818:Animals; D001777:Blood Coagulation; D003094:Collagen / Q000627:therapeutic use; D004337:Drug Carriers; D006470:Hemorrhage / Q000517:prevention & control; D006487:Hemostasis; D006490:Hemostatics; D006801:Humans; D008099:Liver / Q000166:cytology / Q000601:surgery; D008102:Liver Circulation; D008297:Male; D023421:Models, Animal; D011183:Postoperative Complications / Q000628:therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012996:Solutions; D013718:Tensile Strength; D014014:Tissue Adhesives
D004337:Drug Carriers; D006490:Hemostatics; D012996:Solutions; D014014:Tissue Adhesives; C059821:atelocollagen; D003094:Collagen